chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain, Vaccination site swelling, Vaccination site warmth
Clinical narrative: Warmth at injection site; Swelling at injection site; Tenderness at Injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (Warmth at injection site), VACCINATION SITE SWELLING (Swelling at injection site) and VACCINATION SITE PAIN (Tenderness at Injection site) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 042B212A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included OMEPRAZOLE, OXYCODONE, DICYCLOMINE [DICYCLOVERINE], DICLOFENAC, CLOPIDOGREL, VENLAFAXINE, MAGNESIUM OXIDE, METFORMIN, LISINOPRIL, LEVETIRACETAM, PERPHENAZINE, MELATONIN, ROSUVASTATIN, INSULIN ASPART (NOVOLOG) and INSULIN GLARGINE (LANTUS) for an unknown indication.    On 14-Apr-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Apr-2021, the patient experienced VACCINATION SITE WARMTH (Warmth at injection site), VACCINATION SITE SWELLING (Swelling at injection site) and VACCINATION SITE PAIN (Tenderness at Injection site). At the time of the report, VACCINATION SITE WARMTH (Warmth at injection site), VACCINATION SITE SWELLING (Swelling at injection site) and VACCINATION SITE PAIN (Tenderness at Injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No treatment medications were reported.
Sex: U
Vaccine: COVID19
Symptoms: Vaccination complication
Clinical narrative: Side effects from second shot; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 07-Jun-2021 and was forwarded to the company on 07-Jun-2021.    Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a patient and describes the occurrence of VACCINATION COMPLICATION (Side effects from second shot) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (Side effects from second shot). At the time of the report, VACCINATION COMPLICATION (Side effects from second shot) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications reported by investigator  No treatment medications provided by the reporter.
Age: 63.0
Sex: M
Vaccine: COVID19
Symptoms: Parosmia, Sluggishness, Taste disorder
Clinical narrative: everything smelt rotten and had a rotten, burnt chemical smell / s nasty, horrible horrible smell / symptoms have come back stronger; feels sluggish; Nasty horrible horrible smell and taste which overwheles everything I eat; This spontaneous case was reported by a consumer and describes the occurrence of PAROSMIA (everything smelt rotten and had a rotten, burnt chemical smell / s nasty, horrible horrible smell / symptoms have come back stronger), TASTE DISORDER (Nasty horrible horrible smell and taste which overwheles everything I eat) and SLUGGISHNESS (feels sluggish) in a 63-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 026B21A and 001B21A) for COVID-19 vaccination.     The patient's past medical history included Sinus infection (Patient went to his physician who diagnosed him with sinus infection and prescribed antibiotics for 10 days and he felt better).   On 12-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 12-Mar-2021, the patient experienced TASTE DISORDER (Nasty horrible horrible smell and taste which overwheles everything I eat). On 16-Apr-2021, the patient experienced PAROSMIA (everything smelt rotten and had a rotten, burnt chemical smell / s nasty, horrible horrible smell / symptoms have come back stronger) and SLUGGISHNESS (feels sluggish). At the time of the report, PAROSMIA (everything smelt rotten and had a rotten, burnt chemical smell / s nasty, horrible horrible smell / symptoms have come back stronger), TASTE DISORDER (Nasty horrible horrible smell and taste which overwheles everything I eat) and SLUGGISHNESS (feels sluggish) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Sluggishness
Clinical narrative: Felt sluggish; Headache; This spontaneous case was reported by a consumer and describes the occurrence of SLUGGISHNESS (Felt sluggish) and HEADACHE (Headache) in a 49-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 010A21A) for COVID-19 vaccination.     Previously administered products included for Weight loss: Phentermine (30 milligram per day) from June 2020 to May 2021. Concurrent medical conditions included Vegetable allergy (Patient has Asparagus allergy, which results in Swelling, Hives and loss of breath) since 01-Jan-1971, Asthma since 1992, Chronic bronchitis (Patient reports Constant wheezing and trouble sleeping) since 09-Jun-2021, Palpitations (Patient reports that can feel her heart fluttering or skipping beats) since 29-Apr-2021, Joint pain (Severe joint pain throughout her whole body) since 29-Apr-2021, Migraine headache (Has been constant since the 2nd vaccine) since 29-Apr-2021, Nausea (Has been constant since the 2nd vaccine) since 29-Apr-2021, Diarrhea (Has been constant since the 2nd vaccine) since 29-Apr-2021, Rash (Has been constant since the 2nd vaccine) since 29-Apr-2021, Memory loss (Has been constant since the 2nd vaccine) since 29-Apr-2021, Vertigo (Has been constant since the 2nd vaccine) since 29-Apr-2021 and Pain. Concomitant products included OMEPRAZOLE (PRILOSEC [OMEPRAZOLE]) from 19-Apr-2015 to an unknown date for Acid reflux (oesophageal), SUMATRIPTAN for Migraine, IBUPROFEN and OXYCODONE for Pain, MULTIVITAMIN [VITAMINS NOS], CHLORPHENIRAMINE [CHLORPHENAMINE], NORTRIPTYLINE and ATORVASTATIN for an unknown indication.    On 31-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 31-Mar-2021, the patient experienced SLUGGISHNESS (Felt sluggish) and HEADACHE (Headache). The patient was treated with IBUPROFEN for Headache and Sluggishness, at an unspecified dose and frequency. At the time of the report, SLUGGISHNESS (Felt sluggish) and HEADACHE (Headache) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   This case was linked to MOD-2021-212202 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 28-Jul-2021: AE Outcome, Patient demographics provided, Other relevant history added, Concomitant medications added
Sex: U
Vaccine: COVID19
Symptoms: Vaccination complication
Clinical narrative: Side effects; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (Side effects) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (Side effects). At the time of the report, VACCINATION COMPLICATION (Side effects) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Dehydration, Diarrhoea
Clinical narrative: Dehydrated; felt very weak; Acute diarrhea; This spontaneous case was reported by a consumer and describes the occurrence of DIARRHEA (Acute diarrhea), DEHYDRATION (Dehydrated) and ASTHENIA (felt very weak) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 001B21A) for COVID-19 vaccination.     The patient's past medical history included Diarrhea. Concurrent medical conditions included Irritable bowel syndrome.    On 16-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-Mar-2021, the patient experienced DIARRHEA (Acute diarrhea). On an unknown date, the patient experienced DEHYDRATION (Dehydrated) and ASTHENIA (felt very weak). At the time of the report, DIARRHEA (Acute diarrhea), DEHYDRATION (Dehydrated) and ASTHENIA (felt very weak) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       the Concomitant medications were not provided.  Treatments drug included Fluids, Anti Diarrheal.   Most recent FOLLOW-UP information incorporated above includes: On 10-Jun-2021: TCR updated medical history. Irritable bowl syndrome and diarrhea.
Age: 24.0
Sex: F
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration, Maternal exposure during pregnancy
Clinical narrative: she received the second dose 14 days after her first dose; Pregnancy; This spontaneous prospective pregnancy case was reported by a pharmacist and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (she received the second dose 14 days after her first dose) and MATERNAL EXPOSURE DURING PREGNANCY (Pregnancy) in a 24-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 18-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. Last menstrual period and estimated date of delivery were not provided. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (she received the second dose 14 days after her first dose) and MATERNAL EXPOSURE DURING PREGNANCY (Pregnancy). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (she received the second dose 14 days after her first dose) and MATERNAL EXPOSURE DURING PREGNANCY (Pregnancy) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. No treatment medications were reported.  Action taken with mRNA-1273 (Moderna COVID-19 Vaccine) in response to the event was not applicable.
Age: 51.0
Sex: M
Vaccine: COVID19
Symptoms: Testicular pain
Clinical narrative: Discomfort in their right testicle; This spontaneous case was reported by a consumer and describes the occurrence of TESTICULAR PAIN (Discomfort in their right testicle) in a 51-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041821A) for COVID-19 vaccination.     No Medical History information was reported.    On 07-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-May-2021, the patient experienced TESTICULAR PAIN (Discomfort in their right testicle). At the time of the report, TESTICULAR PAIN (Discomfort in their right testicle) outcome was unknown. Unknown      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       No concomitant medications were provided. No treatment details were provided.   This case was linked to MOD-2021-212091 (Patient Link).
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Rash pruritic
Clinical narrative: itchy rash in her back; This spontaneous case was reported by a nurse and describes the occurrence of RASH PRURITIC (itchy rash in her back) in a 53-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 23-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 21-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 23-May-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced RASH PRURITIC (itchy rash in her back). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) for Adverse event, at a dose of 1 dosage form. At the time of the report, RASH PRURITIC (itchy rash in her back) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No Concomitant medications was provided.   Most recent FOLLOW-UP information incorporated above includes: On 27-Jul-2021: TCR attached: Outcome of the event was updated to resolved
Age: 59.0
Sex: M
Vaccine: COVID19
Symptoms: Blood pressure increased, Blood pressure measurement, Headache
Clinical narrative: elevated blood pressure; headache for less than a day; This spontaneous case was reported by a physician and describes the occurrence of BLOOD PRESSURE INCREASED (elevated blood pressure) and HEADACHE (headache for less than a day) in a 59-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 032L20A and 026L20A) for COVID-19 vaccination.     The patient's past medical history included Premature ventricular contractions (Premature Ventricular Contraction) on 01-May-2009. Concurrent medical conditions included Allergy to intravenous contrast media (Allergy to IV contrast) and Shellfish allergy. Concomitant products included METOPROLOL SUCCINATE (TOPROL XL) from 01-May-2009 to an unknown date for Premature ventricular contractions, COLECALCIFEROL (VITAMIN D [COLECALCIFEROL]), FISH OIL and PSYLLIUM HYDROPHILIC MUCILLOID (METAMUCIL [PSYLLIUM HYDROPHILIC MUCILLOID]) for an unknown indication.   On 08-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 05-Feb-2021, the patient experienced HEADACHE (headache for less than a day). On an unknown date, the patient experienced BLOOD PRESSURE INCREASED (elevated blood pressure). On 05-Feb-2021, HEADACHE (headache for less than a day) had resolved. At the time of the report, BLOOD PRESSURE INCREASED (elevated blood pressure) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In 2021, Blood pressure measurement: 120/75 (normal) 120/75.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   The patient reported elevated blood pressure for 2 to 3 weeks, however none of the other symptoms. His blood pressure came to normal several weeks later. No information regarding corrective treatment was reported by the patient.   This case was linked to MOD-2021-004203 (Patient Link).
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Peripheral swelling
Clinical narrative: swelling in hand; This spontaneous case was reported by a consumer and describes the occurrence of PERIPHERAL SWELLING (swelling in hand) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product SARILUMAB (KEVZARA) solution for injection for Rheumatoid arthritis.    Concurrent medical conditions included Left-handedness and Arthritis.   In 2019, the patient started SARILUMAB (KEVZARA) (Subcutaneous) 1 dosage form. On 21-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PERIPHERAL SWELLING (swelling in hand). The patient was treated with PREDNISONE for Swelling, at a dose of 1 dosage form. At the time of the report, PERIPHERAL SWELLING (swelling in hand) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No Concomitant Medications was reported. Patient was transferred to Specialty to get her a new device for the treatment. Patient had an appointment on 18-MAY-2021.
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Myalgia, Rhinorrhoea
Clinical narrative: Feeling little faint; runny nose; left arm is still sore; This spontaneous case was reported by a patient and describes the occurrence of DIZZINESS (Feeling little faint), RHINORRHOEA (runny nose) and MYALGIA (left arm is still sore) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 14-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced DIZZINESS (Feeling little faint), RHINORRHOEA (runny nose) and MYALGIA (left arm is still sore). At the time of the report, DIZZINESS (Feeling little faint), RHINORRHOEA (runny nose) and MYALGIA (left arm is still sore) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication details was reported. No treatment medication details was reported.
Sex: F
Vaccine: COVID19
Symptoms: Feeling abnormal
Clinical narrative: I went online and saw this one lady that had this weird feeling too; This spontaneous case was reported by a consumer and describes the occurrence of FEELING ABNORMAL (I went online and saw this one lady that had this weird feeling too) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 013A21A and 026B21A) for COVID-19 vaccination.     The patient's past medical history included Raynaud's syndrome, Psoriasis (psoriasis in the mouth.), Alopecia, Groin infection and Candida NOS (candida or lichen planus in my mouth.).   On 03-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced FEELING ABNORMAL (I went online and saw this one lady that had this weird feeling too).        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) and mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Axillary pain, Fatigue, Headache, Injection site erythema
Clinical narrative: MUSCLE TIGHTNESS; INJECTION SITE RASH,; INJECTION SITE ERYTHEMA; AXILLARY PAIN; Extreme fatigue; Bad headache; felt like the energy has been drained; This spontaneous case was reported by a consumer and describes the occurrence of MUSCLE TIGHTNESS (MUSCLE TIGHTNESS), INJECTION SITE RASH (INJECTION SITE RASH,), INJECTION SITE ERYTHEMA (INJECTION SITE ERYTHEMA), AXILLARY PAIN (AXILLARY PAIN) and FATIGUE (Extreme fatigue) in an adult female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MUSCLE TIGHTNESS (MUSCLE TIGHTNESS), INJECTION SITE RASH (INJECTION SITE RASH,), INJECTION SITE ERYTHEMA (INJECTION SITE ERYTHEMA), AXILLARY PAIN (AXILLARY PAIN), FATIGUE (Extreme fatigue), HEADACHE (Bad headache) and ASTHENIA (felt like the energy has been drained). At the time of the report, MUSCLE TIGHTNESS (MUSCLE TIGHTNESS), INJECTION SITE RASH (INJECTION SITE RASH,), INJECTION SITE ERYTHEMA (INJECTION SITE ERYTHEMA) and AXILLARY PAIN (AXILLARY PAIN) had resolved, FATIGUE (Extreme fatigue) and HEADACHE (Bad headache) was resolving and ASTHENIA (felt like the energy has been drained) outcome was unknown.            No concomitant drug information provided.  No treatment information provided.   This case was linked to MOD-2021-014798 (Patient Link).   Reporter did not allow further contact
Sex: F
Vaccine: COVID19
Symptoms: Injection site rash, Muscle tightness
Clinical narrative: MUSCLE TIGHTNESS; INJECTION SITE RASH,; INJECTION SITE ERYTHEMA; AXILLARY PAIN; Extreme fatigue; Bad headache; felt like the energy has been drained; This spontaneous case was reported by a consumer and describes the occurrence of MUSCLE TIGHTNESS (MUSCLE TIGHTNESS), INJECTION SITE RASH (INJECTION SITE RASH,), INJECTION SITE ERYTHEMA (INJECTION SITE ERYTHEMA), AXILLARY PAIN (AXILLARY PAIN) and FATIGUE (Extreme fatigue) in an adult female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MUSCLE TIGHTNESS (MUSCLE TIGHTNESS), INJECTION SITE RASH (INJECTION SITE RASH,), INJECTION SITE ERYTHEMA (INJECTION SITE ERYTHEMA), AXILLARY PAIN (AXILLARY PAIN), FATIGUE (Extreme fatigue), HEADACHE (Bad headache) and ASTHENIA (felt like the energy has been drained). At the time of the report, MUSCLE TIGHTNESS (MUSCLE TIGHTNESS), INJECTION SITE RASH (INJECTION SITE RASH,), INJECTION SITE ERYTHEMA (INJECTION SITE ERYTHEMA) and AXILLARY PAIN (AXILLARY PAIN) had resolved, FATIGUE (Extreme fatigue) and HEADACHE (Bad headache) was resolving and ASTHENIA (felt like the energy has been drained) outcome was unknown.            No concomitant drug information provided.  No treatment information provided.   This case was linked to MOD-2021-014798 (Patient Link).   Reporter did not allow further contact
Sex: U
Vaccine: COVID19
Symptoms: Cardiac disorder
Clinical narrative: Heart problems; This spontaneous case was reported by a consumer and describes the occurrence of CARDIAC DISORDER (Heart problems) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced CARDIAC DISORDER (Heart problems). At the time of the report, CARDIAC DISORDER (Heart problems) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications were reported. No treatment information was provided.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Fibromyalgia, Hypersensitivity, Throat tightness
Clinical narrative: Bad flares of fibromyalgia; Allergic reaction; Throat started to close up; This spontaneous case was reported by a consumer and describes the occurrence of FIBROMYALGIA (Bad flares of fibromyalgia), HYPERSENSITIVITY (Allergic reaction) and THROAT TIGHTNESS (Throat started to close up) in a 52-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product TOFACITINIB CITRATE (XELJANZ XR) for Rheumatoid arthritis.    Concurrent medical conditions included Rheumatoid arthritis. Concomitant products included ALBUTEROL SULFATE, HYDROCHLOROTHIAZIDE, TELMISARTAN (TELMISARTAN/HYDROCHLOROTHIAZIDE), METHOTREXATE, GABAPENTIN, DULOXETINE HYDROCHLORIDE (CYMBALTA), NAPROXEN (NAPROSYN E), AMLODIPINE BESYLATE, CYCLOBENZAPRINE HCL, ALPRAZOLAM (XANAX) and ALLOPURINOL for an unknown indication.   On 13-Apr-2021, the patient started TOFACITINIB CITRATE (XELJANZ XR) (Oral) 11 mg once a day. On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced FIBROMYALGIA (Bad flares of fibromyalgia), HYPERSENSITIVITY (Allergic reaction) and THROAT TIGHTNESS (Throat started to close up). At the time of the report, FIBROMYALGIA (Bad flares of fibromyalgia) outcome was unknown and HYPERSENSITIVITY (Allergic reaction) and THROAT TIGHTNESS (Throat started to close up) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   The patient held Xeljanz XR for 1 week after the reaction, due to receiving steroid injection for flares.
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site cellulitis, Vaccination site rash
Clinical narrative: looked like cellulitis; rash at 7 days at the injection site; This spontaneous case was reported by a physician and describes the occurrence of VACCINATION SITE CELLULITIS (looked like cellulitis) and VACCINATION SITE RASH (rash at 7 days at the injection site) in a 50-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE CELLULITIS (looked like cellulitis) and VACCINATION SITE RASH (rash at 7 days at the injection site). At the time of the report, VACCINATION SITE CELLULITIS (looked like cellulitis) and VACCINATION SITE RASH (rash at 7 days at the injection site) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications reported.  Treatment for the events included oral prednisone for 5 days.  Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site cellulitis, Vaccination site rash
Clinical narrative: looked like cellulitis; rash at 7 days at the injection site; This spontaneous case was reported by a physician and describes the occurrence of VACCINATION SITE CELLULITIS (looked like cellulitis) and VACCINATION SITE RASH (rash at 7 days at the injection site) in a 34-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE CELLULITIS (looked like cellulitis) and VACCINATION SITE RASH (rash at 7 days at the injection site). At the time of the report, VACCINATION SITE CELLULITIS (looked like cellulitis) and VACCINATION SITE RASH (rash at 7 days at the injection site) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported.   Treatment for the events included oral prednisone for 5 days.   Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site cellulitis, Vaccination site rash
Clinical narrative: looked like cellulitis; rash at 7 days at the injection site; This spontaneous case was reported by a physician and describes the occurrence of VACCINATION SITE CELLULITIS (looked like cellulitis) and VACCINATION SITE RASH (rash at 7 days at the injection site) in a 22-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE CELLULITIS (looked like cellulitis) and VACCINATION SITE RASH (rash at 7 days at the injection site). At the time of the report, VACCINATION SITE CELLULITIS (looked like cellulitis) and VACCINATION SITE RASH (rash at 7 days at the injection site) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported.   Treatment for the events included oral prednisone for 5 days.  Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site cellulitis, Vaccination site rash
Clinical narrative: looked like cellulitis; rash at 7 days at the injection site; This spontaneous case was reported by a physician (subsequently medically confirmed) and describes the occurrence of VACCINATION SITE CELLULITIS (looked like cellulitis) and VACCINATION SITE RASH (rash at 7 days at the injection site) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE CELLULITIS (looked like cellulitis) and VACCINATION SITE RASH (rash at 7 days at the injection site). At the time of the report, VACCINATION SITE CELLULITIS (looked like cellulitis) and VACCINATION SITE RASH (rash at 7 days at the injection site) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported.   Treatment for the events included oral prednisone for 5 days.   Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site cellulitis, Vaccination site rash
Clinical narrative: looked like cellulitis; rash at 7 days at the injection site; This spontaneous case was reported by a physician and describes the occurrence of VACCINATION SITE CELLULITIS (looked like cellulitis) and VACCINATION SITE RASH (rash at 7 days at the injection site) in a 28-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE CELLULITIS (looked like cellulitis) and VACCINATION SITE RASH (rash at 7 days at the injection site). At the time of the report, VACCINATION SITE CELLULITIS (looked like cellulitis) and VACCINATION SITE RASH (rash at 7 days at the injection site) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported.   Treatment for the events included oral prednisone for 5 days.   Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site cellulitis, Vaccination site rash
Clinical narrative: looked like cellulitis; rash at 7 days at the injection site; This spontaneous case was reported by a physician (subsequently medically confirmed) and describes the occurrence of VACCINATION SITE CELLULITIS (looked like cellulitis) and VACCINATION SITE RASH (rash at 7 days at the injection site) in a 50-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE CELLULITIS (looked like cellulitis) and VACCINATION SITE RASH (rash at 7 days at the injection site). At the time of the report, VACCINATION SITE CELLULITIS (looked like cellulitis) and VACCINATION SITE RASH (rash at 7 days at the injection site) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported.   Treatment for the events included oral prednisone for 5 days.   The mastercase  (MOD-2021-006526) has already been to MR and CP and its non-serious.  Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Sex: M
Vaccine: COVID19
Symptoms: Abdominal pain upper, Asthenia, Eructation, Fatigue, Flatulence
Clinical narrative: Stomach pain; frequent bowel movement, atleast need to go 15-20 times a day; Stomach cramp; Excessive gas,farting; burping; weak; not getting enough sleep because of bathroom trip; hemorrhoid acting up; didn't take his second dose; fatigue; This spontaneous case was reported by a patient and describes the occurrence of ABDOMINAL PAIN UPPER (Stomach pain), FREQUENT BOWEL MOVEMENTS (frequent bowel movement, atleast need to go 15-20 times a day), ABDOMINAL PAIN UPPER (Stomach cramp), FLATULENCE (Excessive gas,farting) and ERUCTATION (burping) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 044A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history provided by reporter.  Concomitant products included OMEPRAZOLE (PRILOSEC [OMEPRAZOLE]), PANCREATIN (CREON), FINASTERIDE, GABAPENTIN, CYANOCOBALAMIN, OXYBUTYNIN, INSULIN, TAMSULOSIN, DULOXETINE HYDROCHLORIDE (CYMBALTA), FUROSEMIDE, SPIRONOLACTONE, BACLOFEN and OXYCODONE for an unknown indication.    On 13-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ABDOMINAL PAIN UPPER (Stomach pain), FREQUENT BOWEL MOVEMENTS (frequent bowel movement, atleast need to go 15-20 times a day), ABDOMINAL PAIN UPPER (Stomach cramp), FLATULENCE (Excessive gas,farting), ERUCTATION (burping), ASTHENIA (weak), SLEEP DEFICIT (not getting enough sleep because of bathroom trip), HAEMORRHOIDS (hemorrhoid acting up), PRODUCT DOSE OMISSION ISSUE (didn't take his second dose) and FATIGUE (fatigue). At the time of the report, ABDOMINAL PAIN UPPER (Stomach pain), FREQUENT BOWEL MOVEMENTS (frequent bowel movement, atleast need to go 15-20 times a day), ABDOMINAL PAIN UPPER (Stomach cramp), FLATULENCE (Excessive gas,farting), ERUCTATION (burping), ASTHENIA (weak), SLEEP DEFICIT (not getting enough sleep because of bathroom trip), HAEMORRHOIDS (hemorrhoid acting up), PRODUCT DOSE OMISSION ISSUE (didn't take his second dose) and FATIGUE (fatigue) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Treatment information was not provided.
Sex: M
Vaccine: COVID19
Symptoms: Frequent bowel movements, Haemorrhoids, Product dose omission issue, Sleep deficit
Clinical narrative: Stomach pain; frequent bowel movement, atleast need to go 15-20 times a day; Stomach cramp; Excessive gas,farting; burping; weak; not getting enough sleep because of bathroom trip; hemorrhoid acting up; didn't take his second dose; fatigue; This spontaneous case was reported by a patient and describes the occurrence of ABDOMINAL PAIN UPPER (Stomach pain), FREQUENT BOWEL MOVEMENTS (frequent bowel movement, atleast need to go 15-20 times a day), ABDOMINAL PAIN UPPER (Stomach cramp), FLATULENCE (Excessive gas,farting) and ERUCTATION (burping) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 044A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history provided by reporter.  Concomitant products included OMEPRAZOLE (PRILOSEC [OMEPRAZOLE]), PANCREATIN (CREON), FINASTERIDE, GABAPENTIN, CYANOCOBALAMIN, OXYBUTYNIN, INSULIN, TAMSULOSIN, DULOXETINE HYDROCHLORIDE (CYMBALTA), FUROSEMIDE, SPIRONOLACTONE, BACLOFEN and OXYCODONE for an unknown indication.    On 13-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ABDOMINAL PAIN UPPER (Stomach pain), FREQUENT BOWEL MOVEMENTS (frequent bowel movement, atleast need to go 15-20 times a day), ABDOMINAL PAIN UPPER (Stomach cramp), FLATULENCE (Excessive gas,farting), ERUCTATION (burping), ASTHENIA (weak), SLEEP DEFICIT (not getting enough sleep because of bathroom trip), HAEMORRHOIDS (hemorrhoid acting up), PRODUCT DOSE OMISSION ISSUE (didn't take his second dose) and FATIGUE (fatigue). At the time of the report, ABDOMINAL PAIN UPPER (Stomach pain), FREQUENT BOWEL MOVEMENTS (frequent bowel movement, atleast need to go 15-20 times a day), ABDOMINAL PAIN UPPER (Stomach cramp), FLATULENCE (Excessive gas,farting), ERUCTATION (burping), ASTHENIA (weak), SLEEP DEFICIT (not getting enough sleep because of bathroom trip), HAEMORRHOIDS (hemorrhoid acting up), PRODUCT DOSE OMISSION ISSUE (didn't take his second dose) and FATIGUE (fatigue) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Treatment information was not provided.
Sex: F
Vaccine: COVID19
Symptoms: Appetite disorder, Asthenia, Communication disorder, Disorientation, Hypoacusis
Clinical narrative: Feels weak; Hearing problem; Appetite problems; Trouble sleeping at night; Issues communicating; Not able to process things; This spontaneous case was reported by a patient and describes the occurrence of ASTHENIA (Feels weak), HYPOACUSIS (Hearing problem), APPETITE DISORDER (Appetite problems), INSOMNIA (Trouble sleeping at night) and COMMUNICATION DISORDER (Issues communicating) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 09-Apr-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ASTHENIA (Feels weak), HYPOACUSIS (Hearing problem), APPETITE DISORDER (Appetite problems), INSOMNIA (Trouble sleeping at night), COMMUNICATION DISORDER (Issues communicating) and DISORIENTATION (Not able to process things). At the time of the report, ASTHENIA (Feels weak), HYPOACUSIS (Hearing problem), APPETITE DISORDER (Appetite problems), INSOMNIA (Trouble sleeping at night), COMMUNICATION DISORDER (Issues communicating) and DISORIENTATION (Not able to process things) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication was reported No treatment medication was reported
Sex: F
Vaccine: COVID19
Symptoms: Insomnia
Clinical narrative: Feels weak; Hearing problem; Appetite problems; Trouble sleeping at night; Issues communicating; Not able to process things; This spontaneous case was reported by a patient and describes the occurrence of ASTHENIA (Feels weak), HYPOACUSIS (Hearing problem), APPETITE DISORDER (Appetite problems), INSOMNIA (Trouble sleeping at night) and COMMUNICATION DISORDER (Issues communicating) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 09-Apr-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ASTHENIA (Feels weak), HYPOACUSIS (Hearing problem), APPETITE DISORDER (Appetite problems), INSOMNIA (Trouble sleeping at night), COMMUNICATION DISORDER (Issues communicating) and DISORIENTATION (Not able to process things). At the time of the report, ASTHENIA (Feels weak), HYPOACUSIS (Hearing problem), APPETITE DISORDER (Appetite problems), INSOMNIA (Trouble sleeping at night), COMMUNICATION DISORDER (Issues communicating) and DISORIENTATION (Not able to process things) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication was reported No treatment medication was reported
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Rash, Skin discolouration, Skin exfoliation, Swelling
Clinical narrative: Skin peeling; Swelling; Skin discoloration; Localised rash; This spontaneous case was reported by a consumer and describes the occurrence of SKIN EXFOLIATION (Skin peeling), SWELLING (Swelling), SKIN DISCOLOURATION (Skin discoloration) and RASH (Localised rash) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.    Co-suspect product included non-company product DUPILUMAB for Dermatitis atopic.    No Medical History information was reported.   In September 2019, the patient started DUPILUMAB (Subcutaneous) 300 milligram. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced SKIN EXFOLIATION (Skin peeling), SWELLING (Swelling), SKIN DISCOLOURATION (Skin discoloration) and RASH (Localised rash). At the time of the report, SKIN EXFOLIATION (Skin peeling) had not resolved, SWELLING (Swelling) and RASH (Localised rash) outcome was unknown and SKIN DISCOLOURATION (Skin discoloration) had resolved.            No treatment medication was reported. Concomitant medication list was not provided.
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity, Somnolence
Clinical narrative: Arm soreness; Drowsy; This spontaneous case was reported by a patient family member or friend and describes the occurrence of PAIN IN EXTREMITY (Arm soreness) and SOMNOLENCE (Drowsy) in an adult female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (Arm soreness) and SOMNOLENCE (Drowsy). At the time of the report, PAIN IN EXTREMITY (Arm soreness) and SOMNOLENCE (Drowsy) outcome was unknown.            The patient's concomitant medication was not reported. It was reported that there were no unusual symptoms. The patient was feeling fine. No treatment information was provided.   This case was linked to MOD-2021-013316, MOD-2021-013316 (Patient Link).
Sex: M
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: Felt like someone punched in the arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Felt like someone punched in the arm) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (Felt like someone punched in the arm). At the time of the report, PAIN IN EXTREMITY (Felt like someone punched in the arm) had not resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported.  No treatment information was reported    This case was linked to MOD-2021-101905.
Sex: M
Vaccine: COVID19
Symptoms: Myalgia
Clinical narrative: significant pain in the arm (that had received the vaccination}" The pain was deep in the muscle and stabbing like , prompting him to "yelp''; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (significant pain in the arm (that had received the vaccination}" The pain was deep in the muscle and stabbing like , prompting him to "yelp'') in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to at an unspecified dose. On an unknown date, the patient experienced MYALGIA (significant pain in the arm (that had received the vaccination}" The pain was deep in the muscle and stabbing like , prompting him to "yelp''). At the time of the report, MYALGIA (significant pain in the arm (that had received the vaccination}" The pain was deep in the muscle and stabbing like , prompting him to "yelp'') outcome was unknown. Not Provided          Concomitant Medications were not provided by the reporter. Treatment Information was not provided by the reporter.